# Infliximab 100mg Powder for Concentrate for Infusion

## Part A

**Prescriber Criteria:** Consultant Dermatologist
Consultant Gastroenterologist
Consultant Paediatrician
Consultant Rheumatologist

**Inpatient use:**

1. Hidradenitis Suppurativa
2. Inflammatory Bowel Diseases
3. Psoriasis
4. Rheumatoid Arthritis

***1. Hidradenitis Suppurativa***

Second line treatment for very severe hidradenitis suppurativa which has shown no improvement after 18 weeks of adalimumab therapy.

***2. IBD - Crohn's Disease:***

- Treatment of severe, active Crohn's disease, in patients who have not responded despite a full and adequate course of therapy with a corticosteroid and an immunosuppressant; or who are intolerant to or have medical contraindications for such therapies, or
- Treatment of fistulising, active Crohn's disease, in patients who have not responded despite a full and adequate course of therapy with conventional treatment (including antibiotics, drainage and immunosuppressive therapy).

***IBD - Ulcerative Colitis:***

Treatment of moderately to severely active ulcerative colitis in patients who have had an inadequate response to conventional therapy including corticosteroids and 6-MP or AZA, or who are intolerant to or have medical contraindications for such therapies.

***3. Extensive Psoriasis:***

Treatment of moderate to severe plaque psoriasis in adult patients who failed to respond to, or who have a contraindication to, or are intolerant to other systemic therapy including cyclosporine, methotrexate or PUVA.

***4. Rheumatoid Arthritis - Stage II or III:***

In combination with methotrexate, for patients with Stage II or III Rheumatoid Arthritis having failed standard therapy as defined by failure to respond to adequate therapeutic trials of:

- at least 2 standard disease-modifying anti-rheumatic drugs (DMARDs) one of which must be methotrexate
- etanercept therapy
- adalimumab therapy.

**An official approval from the Medicines Approval Section (permit) is required.**

**Duration of Approval:**
5 years

## Part B

**Prescriber Criteria:** Consultant Oncologist
Consultant Haematologist

**Inpatient use:**
1. Malignant Diseases

For the management of moderate-to-severe steroid-refractory immune-related adverse events (irAEs).

**Duration of Approval:**
6 months